SCHEMBL179497

SCHEMBL179497

Cc1cc(C(C)(C)C)n[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.50
TSHR P16473 1/20 0.50
MAPT P10636 1/20 0.47
HCAR2 Q8TDS4 2/20 0.40
DAO P14920 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
NPC1 O15118 2/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GAA P10253 2/20 0.35
LMNA P02545 2/20 0.35
PDE10A Q9Y233 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HSD17B10 Q99714 1/20 0.34
DHODH Q02127 1/20 0.34
ALK Q9UM73 1/20 0.33
AURKA O14965 1/20 0.32
AURKB Q96GD4 1/20 0.32
INSR P06213 1/20 0.32
IGF1R P08069 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13184146 0.81 MAPT (0.45) HPGDTSHRMAPTHCAR2DAO
SCHEMBL21233312 0.81 MAPT (0.45) HPGDTSHRMAPTHCAR2DAO
SCHEMBL192831 0.78 DHODH (0.44) HPGDTSHRMAPTHCAR2DAO
SCHEMBL1206509 0.76 HPGD (0.56) HPGDTSHRMAPTHCAR2DAO
SCHEMBL1205789 0.75 HPGD (0.46) HPGDTSHRDAOL3MBTL1NPC1
SCHEMBL16423877 0.75 HPGD (0.55) HPGDTSHRMAPTHCAR2LMNA
SCHEMBL13004470 0.75 HPGD (0.55) HPGDTSHRMAPTLMNAPDE8B
SCHEMBL28214128 0.75 HPGD (0.55) HPGDTSHRMAPTLMNAPDE8B
SCHEMBL12930817 0.75 HPGD (0.55) HPGDTSHRMAPTLMNAPDE8B
SCHEMBL21720026 0.73 HPGD (0.44) HPGDTSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110045191-A1 MIXED-BLOCKED POLYISOCYANATES AND USES THEREOF JONES RICHARD GARFIELD 2011-02-24 US claimed
US-20040067318-A1 Mixed-blocked polyisocyanates and uses thereof BAXENDEN CHEMICALS LIMITED (GB) 2004-04-08 US claimed
EP-1358242-A1 MIXED-BLOCKED POLYISOCYANATES AND USES THEREOF BAXENDEN CHEMICALS LIMITED (GB) 2003-11-05 EP claimed
WO-2002055577-A1 MIXED-BLOCKED POLYISOCYANATES AND USES THEREOF BAXENDEN CHEMICALS LIMITED (GB) 2002-07-18 WO claimed
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 US disclosed
US-20240239809-A1 THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION ARTUS THERAPEUTICS INC (US) 2024-07-18 US disclosed
US-20240209000-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INTELLIKINE LLC 2024-06-27 US disclosed
US-20240209000-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INTELLIKINE LLC 2024-06-27 US disclosed
US-12019371-B2 Photosensitive composition, film, color filter, solid-state imaging element, and image display device FUJIFILM CORPORATION (JP) 2024-06-25 US disclosed
US-12019371-B2 Photosensitive composition, film, color filter, solid-state imaging element, and image display device FUJIFILM CORPORATION (JP) 2024-06-25 US disclosed
EP-4289427-A1 DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR. Anagenesis Biotechnologies (FR) 2023-12-13 EP disclosed
US-20230364097-A1 TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS INFINITY PHARMACEUTICALS, INC. (US) 2023-11-16 US disclosed
EP-1358242-B1 MIXED-BLOCKED POLYISOCYANATES AND USES THEREOF BAXENDEN CHEM (GB) 2006-03-15 EP disclosed
US-6881802-B2 Catalyst for addition polymerization and process for producing an addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-04-19 US disclosed
US-20040067318-A1 Mixed-blocked polyisocyanates and uses thereof BAXENDEN CHEMICALS LIMITED (GB) 2004-04-08 US disclosed
EP-1358242-A1 MIXED-BLOCKED POLYISOCYANATES AND USES THEREOF BAXENDEN CHEMICALS LIMITED (GB) 2003-11-05 EP disclosed
US-20030032743-A1 Catalyst for addition polymerization and process for producing an addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-02-13 US disclosed
EP-1266911-A1 Catalyst for addition polymerization and process for producing an addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-12-18 EP disclosed
WO-2002055577-A1 MIXED-BLOCKED POLYISOCYANATES AND USES THEREOF BAXENDEN CHEMICALS LIMITED (GB) 2002-07-18 WO disclosed
EP-0139183-A2 Herbicidal agents containing a photosynthesis inhibitor herbicide together with substituted azolyl derivatives BAYER AG (DE) 1985-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240209000-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS PIK3CA, PIK3CG, PIK3CD HPGD 2554/4885TSHR 4595/4885MAPT 1341/4885
US-20030032743-A1 Catalyst for addition polymerization and process for producing an addition polymer BRAP, MCM4, BOLA2; BOLA2B HPGD 3876/4885TSHR 4795/4885MAPT 749/4885
US-20250099448-A1 HETEROCYCLIC COMPOUNDS OPRM1, CYP1A1, CYP3A4 HPGD 352/4885TSHR 630/4885MAPT 2210/4885
US-20240239809-A1 THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION LIPG, FABP2, EPCAM HPGD 339/4885TSHR 4301/4885MAPT 3610/4885
US-20230364097-A1 TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS PIK3CA, MCL1, PIK3CB HPGD 2431/4885TSHR 2387/4885MAPT 4584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.